IBRX FY 2016 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44,000-81.4% YoY

Gross Profit

$44,000100.0% margin

Operating Income

-$125M-282954.5% margin

Net Income

-$121M-274565.9% margin

EPS (Diluted)

$-0.37

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$45M

Stock-Based Comp.

$74M

Balance Sheet

Total Assets

$317M

Total Liabilities

$24M

Stockholders' Equity

$293M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44,000	$236,000	-81.4%
Gross Profit	$44,000	$236,000	-81.4%
Operating Income	-$125M	-$239M	+47.9%
Net Income	-$121M	-$237M	+49.0%